Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ: MDWD )

18.76 +0.14 (+0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
3 Micro-Cap Stocks to Buy for Multibagger Returns
These are the micro-cap stocks to buy and they represent companies with decent fundamentals and visibility for robust growth. 
Via InvestorPlace
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
From MediWound Ltd.
Via GlobeNewswire
Recap: MediWound Q1 Earnings
Via Benzinga
Earnings Outlook For MediWound
Via Benzinga
5 Analysts Have This to Say About MediWound
Via Benzinga
Earnings Scheduled For May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter. 
Via Benzinga
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
Preview: MediWound's Earnings
Via Benzinga
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
Via Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
Via Benzinga
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via GlobeNewswire
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market... 
Via Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.